News and Updates

Researchers report promising safety and biomarker results in a Phase 1 trial for a new siRNA-based treatment targeting SOD1-associated ALS.

Vietnam’s pharma sector is set to exceed $10B as aging demographics and new regulatory reforms spark rapid growth in the regional healthcare market.

Over half of all clinical trial sites struggle with patient loss due to inefficiencies. Discover the operational fixes needed to boost retention and R&D.

ORIC Pharmaceuticals has launched the Phase 3 Himalayas-1 trial, testing rinzimetostat as a targeted treatment for metastatic castration-resistant prostate cancer.

New clinical trial data shows the combination of sac-TMT and pembrolizumab hits primary endpoints for patients with PD-L1-negative NSCLC. Read more here.

Discover how clinical trial simulation and digital twins are slashing R&D costs and accelerating drug development by replacing traditional research models.

The FDA has granted Priority Review to Gazyva for Primary Membranous Nephropathy. Explore how this CD20-directed therapy could transform kidney care.

Lynk Pharmaceuticals completes enrollment for its Phase III trial of Zemprocitinib, a promising new JAK inhibitor for treating Ankylosing Spondylitis.

Veradermics announces Phase 2 results for VDPHL01, a potential new treatment for mild-to-moderate female pattern hair loss. Get the latest clinical trial data.

The WHO has launched the first clinical trial to test an antiviral for the deadly Bundibugyo Ebola strain. Discover the impact on future outbreak control.